IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022

Rhea-AI Summary

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will hold an earnings conference call on September 14, 2022, at 10:30 am Eastern Time, to discuss its first-quarter fiscal year 2023 results. The financial results will be released prior to the call, and management will answer pre-submitted questions from investors. Participants can join via the provided toll-free and toll dial-in numbers. The call will also be accessible online and available for replay on the company’s investor relations page.

The Company to host an earnings conference call via webcast

VICTORIA, British Columbia--(BUSINESS WIRE)-- IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.

ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested in submitting questions ahead of the call are encouraged to email the Company’s investor relations contact.

Conference Call:

Date: Wednesday, September 14, 2022
Time: 10:30 am Eastern time

Participant Info:

Conference ID: 9236374
Participant Toll-Free Dial-In Number: 1 (888) 550-5658
Participant Toll Dial-In Number: 1 (646) 960-0289

Attendee URL: https://events.q4inc.com/attendee/349012238

The conference call will be webcast live and available for replay via a link provided in the Events section of the company’s IR pages at https://www.immunoprecise.com/investors.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company's periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a biotherapeutic research and technology company that leverages network biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005667/en/

Investor contact: investors@immunoprecise.com

Source: ImmunoPrecise Antibodies Ltd.

FAQ

When is ImmunoPrecise Antibodies' next earnings call?

ImmunoPrecise Antibodies will host its next earnings call on September 14, 2022, at 10:30 am Eastern Time.

How can I listen to the ImmunoPrecise earnings call?

You can listen to the ImmunoPrecise earnings call by dialing 1 (888) 550-5658 for toll-free access or 1 (646) 960-0289 for toll access. The call will also be available for streaming on their investor relations website.

What will be discussed in the upcoming earnings call?

The earnings call will cover the quarterly results for the first quarter of fiscal year 2023 and recent business highlights.

Are there opportunities to submit questions for the ImmunoPrecise earnings call?

Yes, investors can submit questions ahead of the earnings call to the company's investor relations contact.

Where can I find the financial results from ImmunoPrecise Antibodies?

Financial results will be released in a press release prior to the earnings call and can also be found on the company's investor relations page.